ArticleOncotarget2017
Annexin A13 promotes tumor cell invasion in vitro and is associated with metastasis in human colorectal cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Annexin A13 Protects Against Acute Kidney Injury by Inactivating TGF-β/Smad3 Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- ANXA13 expression patterns in hepatocellular carcinoma and impact on tumor behavior.World journal of gastrointestinal surgery · 2025Article
- Comprehensive dissection of cis-regulatory elements in a 2.8 Mb topologically associated domain in six human cancers.Nature communications · 2025Article
- ANXA13 promotes cell proliferation and invasion and attenuates apoptosis in renal cell carcinoma.Heliyon · 2023Article
- Potential prognostic and therapeutic value of ANXA8 in renal cell carcinoma: based on the comprehensive analysis of annexins family.BMC cancer · 2023Article
- Annexin A protein family: Focusing on the occurrence, progression and treatment of cancer.Frontiers in cell and developmental biology · 2023Review
- Transcriptome analysis of intestine from alk-SMase knockout mice reveals the effect of alk-SMase.Cancer cell international · 2022Article
- Pathobiological functions and clinical implications of annexin dysregulation in human cancers.Frontiers in cell and developmental biology · 2022Review
- Tracking the Antibody Immunome in Sporadic Colorectal Cancer by Using Antigen Self-Assembled Protein Arrays.Cancers · 2021Article
- Integrative analysis reveals novel driver genes and molecular subclasses of hepatocellular carcinoma.Aging · 2020Article
- Developing prognostic gene panel of survival time in lung adenocarcinoma patients using machine learning.Translational cancer research · 2020Article
- Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.Journal of translational medicine · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAberrantly upregulated expression of selected members of annexin, a group of calcium- and membrane-binding proteins, have been found to be associated with metastasis, poor prognosis, and other clinical characteristics in colorectal cancer (CRC), the third most diagnosed cancer. However, ANXA13 (encoding protein annexin A13), the original founder gene of the annexin A family, has not been studied carefully as a potential prognostic biomarker in CRC.
methodsThe protein level of annexin A13 was determined by western blot in a panel of CRC cell lines. Tumor cell invasion was determined by a Matrigel in vitro invasion assay in selected CRC cells with either upregulated (via plasmid transfection) or downregulated (via siRNA treatment) expression of ANXA13. The clinicopathological features and prognostic values associated with ANXA13 expression were also evaluated in a group of 125 CRC patients.
resultsANXA13 was expressed at a high level in HCT116 and HT29 cells but undetected or at a lower level in SW620, SW48, and Rko cells. CRC cell invasion was promoted by ANXA13 overexpression in SW620 or Rko cells and was reduced by ANXA13 downregulation in HCT116 or HT29 cells. In CRC patients, ANXA13 expression levels correlated with lymph node metastasis and were associated with poor overall survival.
conclusionsANXA13 is associated with CRC cell invasion in vitro, and with lymph node metastasis and poor survival in CRC patients. Our results indicate that ANXA13 can be exploited as a biomarker for its diagnostic and prognostic values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.